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The HIV Nef protein downregulates the cell-surface
expression of the HIV receptor glycoprotein CD4, but
the significance of this event has remained obscure.
Recent data suggest that Nef reduces cell-surface CD4
to promote the efficient spread of the virus.
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The human immunodeficiency virus (HIV) Nef protein
has a number of apparently independent functions in vitro
and has been shown to be absolutely required for viral
pathogenesis in vivo. This requirement was first demon-
strated by the observation that a mutant form of simian
immunodeficiency virus (SIV) that lacked Nef failed to
induce disease in macaque monkeys [1]. Further support
was provided by data published last year demonstrating
that transgenic mice, in which expression of Nef alone (in
the absence of other viral gene products) was restricted to
CD4-positive cells, exhibited symptoms of AIDS-like
pathology [2]. At present, the significance of the various
in vitro functions of Nef to the activity of the protein
in vivo is the subject of debate. Two papers published in
this issue of Current Biology [3,4] address this topic and
provide evidence that downregulation of cell-surface CD4
by Nef is important for the spread of HIV from the
infected cell, an observation with clear implications for
viral replication in vivo.
More than a decade of research on Nef has defined three
main in vitro functions of the protein [5]. Firstly, expres-
sion of Nef in productively infected cells enhances the
infectivity of HIV particles released from these cells. Nef
is a myristoylated protein and a subset of cellular Nef is
located at the plasma membrane, thus becoming incorpo-
rated into budding virus particles. Virions that contain
Nef are able to undergo reverse transcription more effi-
ciently upon entry into the next host cell; although the
mechanism for this enhancement is obscure, it has been
suggested to involve the recruitment of a kinase to the
virus particle. Secondly, Nef has been reported to have
diverse effects on cellular signal transduction path-
ways — there is little general consensus in this area and
most experiments have been performed in cells express-
ing Nef in the absence of other viral proteins and thus the
significance for virus replication as a whole remains to be
proven. It is clear, however, that Nef interacts with a
number of cellular protein kinases, and acts both as a
kinase substrate and as a modulator of kinase activity. 
Finally, Nef has been demonstrated by many groups to
downregulate cell-surface expression of CD4, a phenome-
non first observed in 1987 but not studied further until
1993. Studies into the mechanism have demonstrated that
Nef binds not only to CD4 [6] but also to components of
clathrin-coated pits — the µ chains of adaptor-protein com-
plexes [7] and the catalytic subunit of the vacuolar ATPase
(V-ATPase) [8]. The binding of Nef to CD4 is mediated
by interactions between the region corresponding to amino
acids 61–110 of Nef and a dileucine motif in the cytoplas-
mic domain of CD4. Residues in an unstructured loop near
the carboxyl terminus of Nef, including another dileucine
motif and a conserved acidic cluster, mediate binding to
the µ chain and to V-ATPase.
These interactions, therefore, suggest that Nef acts as a
linker to recruit CD4 into clathrin-coated pits and subse-
quently accelerate its endocytosis (Figure 1). The endo-
cytosed CD4 accumulates in early endosomes where it is
subjected to a sorting process and either recycled to the
cell surface or passed to lysosomes for degradation. Nef
also appears to affect this sorting by diverting CD4 into
the lysosomal pathway, presumably as a result of inter-
actions with the V-ATPase, which is involved in endo-
some acidification. As an aside, Nef has also been shown
to downregulate cell-surface major histocompatibility
complex (MHC) class I molecules, although the mecha-
nism of this effect has been reported to be distinct from
that involved in CD4 downregulation, because it
requires a tyrosine-based endocytosis signal in the MHC
class I molecules.
In addition to Nef, two other HIV proteins are involved in
decreasing the cell-surface expression of CD4. Inter-
actions between CD4 and the viral envelope glycoprotein
gp160 (the product of the env gene that is subsequently
cleaved by endoplasmic reticulum/Golgi resident pro-
teases into gp120 and gp41 subunits) during protein syn-
thesis results in the sequestration of the CD4–gp160
complex in the endoplasmic reticulum [9]. As well as
reducing cell-surface levels of CD4, clearly this is bad
news for the virus as it will prevent migration of gp160 to
the plasma membrane where it is needed to take part in
the assembly of infectious virus particles, which bud
directly from the plasma membrane. HIV type 1 (HIV-1)
encodes a small accessory protein Vpu; uniquely the
expression of both Vpu and gp160 are coordinated
because the genes for these proteins are carried in a
bicistronic mRNA molecule. Vpu is an integral membrane
phosphoprotein that, like Nef, binds to the cytoplasmic
domain of CD4. Vpu then mediates the translocation of
CD4 to the cytosol and promotes CD4 degradation by a
mechanism that involves the cytosolic ubiquitin–protea-
some pathway [10] (Figure 1).
So why does HIV have mechanisms for reducing the cell-
surface expression of CD4? The two papers [3,4] pub-
lished in this issue provide a partial explanation to this
conundrum. Ross et al. [3] and Lama et al. [4] show that
high levels of CD4 on the cell surface interfere with the
production and release of infectious virus particles from
the cell. The two groups propose different mechanisms to
account for this inhibition, however. Ross et al. [3] demon-
strate that high levels of surface CD4 reduce the overall
amount of virus released from the cell, but find that the
absolute infectivity of released virus is unaffected. In con-
trast, Lama et al. [4] suggest that, in the presence of high
levels of surface CD4, the virus released has a reduced
envelope glycoprotein content and is consequently less
infectious than virus released from CD4-negative cells.
Given that both groups used similar experimental
systems, this discrepancy will clearly need to be
addressed. At a virological level, however, the implication
of the results presented in both of these studies is that the
spread of HIV from an infected cell is inhibited by cell-
surface CD4. Importantly, both groups [3,4] show that the
CD4-mediated inhibition of the spread of HIV is relieved
by expression of Nef, and Lama et al. [4] observe that Vpu
can also block this inhibition. 
There are two reasons why the virus should need Nef as
well as Vpu and gp160 for CD4 downregulation.
Although Vpu and gp160 will interfere with the fate of
newly synthesised CD4, they will have no effect on the
pre-existing levels of cell-surface CD4. Neither will they
affect the fate of CD4 that is recycled from endosomes
back to the cell surface. Furthermore, in T cells CD4 is
stabilised at the cell surface by an interaction between its
cytoplasmic domain and the Src-family tyrosine kinase
Lck and this stabilisation prevents CD4 from associating
with clathrin-coated pits, meaning that HIV needs a
mechanism to actively promote CD4 endocytosis. Also,
Nef has been shown to be expressed at high levels early
in the virus replication cycle, before the expression of
Env and Vpu. Thus, we can envision a scenario in which
early expression of Nef results in a dramatic reduction in
the levels of cell-surface CD4. The subsequent lack of
CD4 at the cell surface allows the successful assembly of
HIV virion particles.
There are two other possible reasons why Nef-mediated
CD4 downregulation might be beneficial to the virus.
Firstly, it could inhibit reinfection by more HIV particles.
Downregulation of CD4 by SIV Nef has been shown to
prevent subsequent infection of human T cells with
HIV-1, and there is evidence from in vitro studies that rein-
fection of HIV-infected T cells results in the accumulation
of viral DNA but does not augment production of virus
particles. Presumably this is because reinfection effectively
‘overloads’ the biosynthetic capability of the cell. Although
this is unlikely to be relevant in the periphery in vivo, it
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Figure 1
HIV uses multiple mechanisms for reducing
the cell-surface levels of CD4. At the plasma
membrane, Nef interacts with both the
cytoplasmic domain of cell-surface CD4 and
components of clathrin-coated pits, thus
recruiting CD4 into the endocytic pathway.
Instead of recycling from early endosomes to
the cell surface, CD4 is sorted into lysosomes
for degradation. Newly synthesised CD4 and
HIV Env gp120 and gp41 proteins associate
in the endoplasmic reticulum where the
complex is sequestered. Vpu interacts with
the cytoplasmic domain of CD4 in the
endoplasmic reticulum and mediates
translocation of CD4 into the cytosol, CD4
ubiquitination and targeting of CD4 to
proteasomes. Env is then free to be exported
to the cell surface.
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may be important in HIV-infected lymph nodes where
there are likely to be high levels of virus.
Secondly, there is evidence that signals transduced
through the cytoplasmic domain of CD4 can result in the
inhibition of transcription mediated by the HIV long ter-
minal repeat, which is the promoter for the viral genes [11].
These signals were induced in vitro by the binding of mon-
oclonal antibodies to a specific extracellular region, the
immunoglobulin complementarity determining region 3
(CDR3)-like region of CD4, but not to the CDR2-like
region of CD4, which is also located in the amino-terminal
(D1) extracellular domain of CD4. It is possible, however,
that similar signals might be induced in vivo by the binding
of the physiological CD4 ligand, interleukin-16 (IL-16), to
the CDR3-like region. IL-16 induces CD4 clustering and
subsequent signalling events, including a rise in the levels
of intracellular calcium and inositol (1,4,5)-trisphosphate
[12]. Intriguingly, the CDR3 region of CD4 has been
reported to be involved in CD4 dimerisation. Presumably,
one effect of Nef-mediated CD4 downregulation would be
to prevent the transduction of these signals that negatively
regulate HIV transcription and concomitant virus produc-
tion. Clearly this effect of Nef would be important early in
the virus replication cycle. So, although Ross et al. [3] and
Lama et al. [4] demonstrate an important consequence of
Nef-mediated CD4 downregulation in terms of viral trans-
mission, the other potential consequences of CD4 down-
regulation merit further investigation. 
These two new papers raise a critical issue, however, that
should be a priority for future research. The results should
be extended either to transformed T-cell lines or prefer-
ably to primary lymphocytes in order to confirm the in vivo
relevance of this phenomenon at CD4 expression levels
that accurately reflect the physiological levels found on the
HIV-infected host cell. Furthermore, in a broader context
Nef represents a good example of how viruses have
evolved to cope with a limited set of genes by producing
proteins that have a wide variety of functions. Although
light has now been shed on the biological significance of
one of the in vitro functions of Nef, the challenge now is to
determine whether other in vitro functions of the protein
are also important for Nef action in vivo. If they are, the
race will be on to develop new chemotherapeutic agents to
fight HIV that are targeted against Nef function.
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